Medidur trial completes enrolment

Alimera Sciences and pSivida have completed enrolment for the FAME (Fluocinolone Acetonide in diabetic Macular Edema) study of Medidur.

Alimera Sciences and pSivida have completed enrolment for the FAME (Fluocinolone Acetonide in diabetic Macular Edema) study of Medidur.

FAME is a double-masked, randomized, multicentre study that has now enrolled 900 patients across the US, Canada, Europe and India and will assess the safety and efficacy of Medidur for the treatment of diabetic macular oedema (DME).

An independent Data Safety Monitoring Board (DSMB) has recently recommended that the pivotal Phase III clinical trial continue under the current protocol, without change.

Medidur is a tiny, injectable insert that delivers fluocinolone acetonide, a corticosteroid, to the retina for up to three years.

Related Videos
Fluid dynamics in wet macular degeneration: How fluid type affects visual acuity
EURETINA leadership discusses what to expect at the 2022 Congress, outlines Women in Retina programme
Paediatric eyes repair better with scleral buckling, adults need vitrectomy only for giant retinal tear-related detachments
Related Content
© 2023 MJH Life Sciences

All rights reserved.